Novartis' board of directors proposed that shareholders redeem 32,640,000 shares, reducing share capital by 1.32%. These securities were purchased as part of the eighth buyback program. The board also proposed that it be authorized to repurchase CHF 10 billion worth of shares through 2024. Shareholders will consider these proposals at the annual general meeting on March 2, 2021.